Core Insights - Ardent Health Corporation (ARDT) is set to release its quarterly earnings on March 4, 2026, with analysts predicting an earnings per share (EPS) of $0.34 and revenue of approximately $1.63 billion [1][6] Legal Issues - ARDT is currently facing a securities fraud class action lawsuit due to undisclosed collections problems, which have resulted in a 33% decline in its stock value [2][6] - Investors who purchased securities between July 18, 2024, and November 12, 2025, are encouraged to file lead plaintiff applications by March 9, 2026 [2] Financial Metrics - The company has a price-to-earnings (P/E) ratio of 6.45, indicating a relatively low valuation compared to its earnings [3][6] - ARDT's price-to-sales ratio is 0.21, meaning investors pay 21 cents for every dollar of sales [3] - The enterprise value to sales ratio is 0.48, reflecting its valuation in relation to revenue [3] - The enterprise value to operating cash flow ratio stands at 8.28, suggesting a moderate valuation based on cash flow [4] - ARDT's earnings yield is 15.50%, providing a measure of return on investment for shareholders [4] - The debt-to-equity ratio of 1.84 indicates a significant reliance on debt in its capital structure [4][6] - The current ratio of 2.08 suggests a strong ability to cover short-term liabilities with short-term assets [5]
Ardent Health Corporation (NYSE:ARDT) Faces Legal Challenges Amid Financial Reporting